Have a personal or library account? Click to login
Formulation and evaluation of controlled release ocusert of gatifloxacin and prednisolone Cover

Formulation and evaluation of controlled release ocusert of gatifloxacin and prednisolone

Open Access
|Dec 2021

Abstract

Objective: Ocuserts are sterile, solid, or semisolid dosage forms prepared to attain increased contact time between the drug and the conjunctival tissue to keep up a constant release of drug when placed in the lower cul-de-sac or conjunctival sac of the eye. The aim of formulating this delivery system was to treat both inflammatory and infectious conditions of the eye with increased ocular residence time by releasing drugs at a slow and constant rate.

Method: Gatifloxacin, and prednisolone ocuserts were prepared by solvent casting method, and evaluated for physical appearance, uniformity of weight, thickness, folding endurance, drug content, surface pH, in-vitro, and ex-vivo release profile.

Results: All formulated inserts exhibited positive results in terms of their evaluation parameters. Ocuserts were sterile, with no turbidity in selected media during the study, and they were stable throughout six months.

Conclusion: Results suggested that prepared optimized ocusert formulation would be a suitable alternative to eye drops for treating conjunctivitis and other bacterial infections.

DOI: https://doi.org/10.2478/amma-2021-0032 | Journal eISSN: 2668-7763 | Journal ISSN: 2668-7755
Language: English
Page range: 227 - 237
Submitted on: Aug 11, 2021
Accepted on: Oct 15, 2021
Published on: Dec 30, 2021
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2021 Navneet Nagpal, Sukhmanpreet Singh, Guraasdeep Kaur, Parminderjit Kaur, Ravi Kumar Dhawan, Mandeep Singh Chhina, Manisha Arora, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.